Leap Therapeutics’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Leap Therapeutics researches, develops and commercializes monoclonal antibodies that enable immune system to identify and attack cancer cells. Read more

7 Followers on Owler
7 Followers on Owler
7 Followers on Owler
7 Followers on Owler

Leap Therapeutics researches, develops and commercializes monoclonal antibodies that enable immune system to identify and attack cancer cells. Read more

Chris Mirabelli's photo - CEO of Leap Therapeutics

CEO

Chris Mirabelli

CEO Approval Rating

73/100

Founded:

2011

Status:

PublicIndependent CompanyNASDAQLPTX

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Juno is one of Leap Therapeutics's top rivals. Juno was founded in Seattle, Washington} in 2013. Like Leap Therapeutics, Juno also competes in the Pharmaceuticals space. Compared to Leap Therapeutics, Juno generates $104.9M more revenue.

Altor BioScience is Leap Therapeutics's #2 competitor. Altor BioScience was founded in 2002, and is headquartered in Miramar, Florida. Like Leap Therapeutics, Altor BioScience also operates in the Pharmaceuticals space. Altor BioScience generates $5.1M more revenue vs. Leap Therapeutics.

AVROBIO is a top competitor of Leap Therapeutics. AVROBIO's headquarters is in Cambridge, Massachusetts, and was founded in 2015. AVROBIO is in the Biotechnology industry. AVROBIO generates 104% of Leap Therapeutics's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Kite Pharma a competitor of Leap Therapeutics?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$1.1M

Leap Therapeutics's revenue is the ranked 20th among it's top 10 competitors. The top 10 competitors average 9B. Over the last three quarters, Leap Therapeutics's revenue has decreased by 0%. Specifically, in Q3 2020's revenue was $ < 1M; in Q2 2020, it was $ < 1M; in Q1 2020, it was $ < 1M.

Acquisitions

No recent acquisitions found related to Leap Therapeutics

Leap Therapeutics Funding History

$9.9M$27.9M$54.9M

Since Leap Therapeutics was founded in 2011, it has participated in 3 rounds of funding. In total Leap Therapeutics has raised $54.9M. Leap Therapeutics' last funding round was on Jan 2020 for a total of $27.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Jan 2020
$27M

BeiGene, Ltd.

Private Placement
Nov 2017
$18M
-
Equity
Jan 2011
$9.9M
-

Since Leap Therapeutics was founded in 2011, it has participated in 3 rounds of funding. In total Leap Therapeutics has raised $54.9M. Leap Therapeutics' last funding round was on Jan 2020 for a total of $27.0M

Investments

No recent investments found related to Leap Therapeutics

Leap Therapeutics News

September 9, 2020MarketScreener

to Present at H.C. Wainwright 22nd Annual Global Investment Conference

(marketscreener.com) CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. , a biot... See more »
August 24, 2020MarketScreener

Expands Leadership Team with Addition of Two Industry Veterans

(marketscreener.com) CAMBRIDGE, Mass., Aug. 24, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. , a biot... See more »
August 16, 2020Zolmax News

Leap Therapeutics Inc (NASDAQ:LPTX) Expected to Announce Earnings of -$0.17 Per Share

Brokerages forecast that Leap Therapeutics Inc (NASDAQ:LPTX) will post earnings per share (EPS) of ($... See more »
August 13, 2020BioSpace

Leap Therapeutics Reports Second Quarter 2020 Financial Results

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology t... See more »
July 1, 2020Zolmax News

Leap Therapeutics Inc (NASDAQ:LPTX) Expected to Post Earnings of -$0.26 Per Share

Equities research analysts expect Leap Therapeutics Inc (NASDAQ:LPTX) to report ($0.26) earnings per ... See more »

Leap Therapeutics Press Releases

January 23, 2020centralcharts

Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting

Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI)... See more »
September 17, 2019PR Newswire

Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination at the 2019 International Gynecologic Cancer Society Annual Global Meeting

CAMBRIDGE, Mass., Sept. 17, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX) today announc... See more »
April 3, 2019PR Newswire

Leap Therapeutics to Present at the 2019 Needham & Company 18th Annual Healthcare Conference

CAMBRIDGE, Mass., April 3, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnolo... See more »
April 1, 2019PR Newswire

Leap Therapeutics Reports Clinical Update and 2018 Financial Results

CAMBRIDGE, Mass., April 1, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnolo... See more »
March 18, 2019PR Newswire

Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer

CAMBRIDGE, Mass., March 18, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX) today announce... See more »
March 8, 2019centralcharts

Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer

CAMBRIDGE, Mass., March 8, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnolo... See more »
February 5, 2019CentralCharts

Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and im... See more »

Social Media

Headquarters

47 Thorndike St Ste B1-1 Suite B1-1

Cambridge, Massachusetts02141

1-617-714-0360

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Leap Therapeutics researches, develops and commercializes monoclonal antibodies that enable immune system to identify and attack cancer cells. Leap Therapeutics was founded in 2011. Leap Therapeutics' headquarters is located in Cambridge, Massachusett...

CEO

Leap Therapeutics's CEO, Chris Mirabelli, currently has an approval rating of 73%. Leap Therapeutics's primary competitors are Juno, Altor BioScience & AVROBIO.

Website

leaptx.com

Frequently Asked Questions about Leap Therapeutics

  1. When was Leap Therapeutics founded?

    Leap Therapeutics was founded in 2011
  2. Who is Leap Therapeutics's CEO?

    Leap Therapeutics's CEO is Chris Mirabelli
  3. How much revenue does Leap Therapeutics generate?

    Leap Therapeutics generates $1.1M in revenue
  4. How much funding does Leap Therapeutics have?

    Leap Therapeutics has historically raised $54.9M in funding
  1. Where is Leap Therapeutics's headquarters?

    Leap Therapeutics's headquarters is in Cambridge Massachusetts, USA
  2. How many employees does Leap Therapeutics have?

    Leap Therapeutics has 24 employees
  3. What sector does Leap Therapeutics operate in?

    Leap Therapeutics is in Pharmaceuticals
  4. Who are Leap Therapeutics's competitors?

    Leap Therapeutics's top competitors are Juno, Altor BioScience, AVROBIO